View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonst...

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers Programmable epigenomic mRNA candidates enabled durable and robust upregulation of gene expression across a diverse set of gene types and regulatory mechanismsAdditional OMEGA platform capabilities demonstrated, including reversible downregulation and multiplexed upregulation of gene expression CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company ...

Daniel Ives ... (+5)
  • Daniel Ives
  • John Katsingris
  • Matthew Weiss
  • Michael Gerbino
  • Scott Devitt
 PRESS RELEASE

Omega Therapeutics Reports First Quarter 2024 Financial Results and Hi...

Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024Presented new preclinical data demonstrating potential of a MYC-targeting epigenomic controller in NSCLC at AACR 2024Company to present new preclinical data demonstrating durable epigenomic upregulation and other OMEGA platform capabilities at ASGCT 2024 CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- O...

Wedbush Research
  • Wedbush Research
MTB M&T BANK CORPORATION
SIVB SVB FINANCIAL GROUP
USB U.S. BANCORP
ZION ZIONS BANCORPORATION N.A.
WTFC WINTRUST FINANCIAL CORPORATION
WING WINGSTOP INC.
WBS WEBSTER FINANCIAL CORPORATION
WAL WESTERN ALLIANCE BANCORP
VLY VALLEY NATIONAL BANCORP
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
SBNY SIGNATURE BANK
RF REGIONS FINANCIAL CORPORATION
PZZA PAPA JOHN'S INTERNATIONAL INC.
PPBI PACIFIC PREMIER BANCORP INC.
PB PROSPERITY BANCSHARES INC.(R)
NYCB NEW YORK COMMUNITY BANCORP INC.
KEY KEYCORP
JACK JACK IN THE BOX INC.
HMST HOMESTREET INC.
HBAN HUNTINGTON BANCSHARES INCORPORATED
HAFC HANMI FINANCIAL CORPORATION
FRC FIRST REPUBLIC BANK
FITB FIFTH THIRD BANCORP
FHN FIRST HORIZON CORPORATION
FFWM FIRST FOUNDATION
EWBC EAST WEST BANCORP INC.
ETSY ETSY INC.
DIN DINE BRANDS GLOBAL INC.
CVBF CVB FINANCIAL CORP.
CUBI CUSTOMERS BANCORP INC.
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
COLB COLUMBIA BANKING SYSTEM INC.
CHUY CHUY'S HOLDINGS INC.
CFG CITIZENS FINANCIAL GROUP INC.
CATY CATHAY GENERAL BANCORP
CAKE CHEESECAKE FACTORY INCORPORATED
BZH BEAZER HOMES USA INC.
BXP BOSTON PROPERTIES INC.
BKU BANKUNITED INC.
BANC BANC OF CALIFORNIA INCORPORATED
GRBK GREEN BRICK PARTNERS
CFR CULLEN/FROST BANKERS INC.
BOKF BOK FINANCIAL CORPORATION
CMA COMERICA INCORPORATED
EA ELECTRONIC ARTS INC.
SLM SLM CORP
TSC TRISTATE CAPITAL HOLDINGS INC
ZNGA ZYNGA INC. CLASS A
HOPE HOPE BANCORP INC.
CVNA CARVANA CO. CLASS A
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
ZG ZILLOW GROUP INC. CLASS A
TENB TENABLE HOLDINGS
AX AXOS FINANCIAL INC.
UBER UBER TECHNOLOGIES INC.
LC LENDINGCLUB CORP
SI SILVERGATE CAPITAL
U UNITY SOFTWARE
DASH DOORDASH
SOFI SOFI TECHNOLOGIES INC
APP APPLOVIN CORP
NAPA DUCKHORN PORTFOLIO INC (THE)
BROS DUTCH BROS INC
CAVA CAVA GROUP INC
 PRESS RELEASE

Omega Therapeutics to Present New Preclinical Data on Epigenomic Upreg...

Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will present a poster at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, MD, May 7 – 11, 2024. The poster will feature new preclinical data that dem...

 PRESS RELEASE

Monarch Casino & Resort Reports Record First Quarter 2024 Financial Re...

Monarch Casino & Resort Reports Record First Quarter 2024 Financial Results Declares Cash Dividend of $0.30 per Share Payable on June 15, 2024 RENO, Nev., April 17, 2024 (GLOBE NEWSWIRE) -- Monarch Casino & Resort, Inc. (Nasdaq: MCRI) (“Monarch,” “we,” “our,” or “the Company”) today reported operating results for the first quarter ended March 31, 2024, as summarized below: ($ in thousands, except per share data and percentages)   Three Months Ended March 31,  2024 2023 IncreaseNet revenue $121,657  $116,644  4.3% Net income  18,275   17,670  3.4% Adjusted EBITDA (1) $38,548  $36,480  5....

 PRESS RELEASE

Monarch Casino & Resort to Report 2024 FIRST Quarter Results AFTER MAR...

Monarch Casino & Resort to Report 2024 FIRST Quarter Results AFTER MARKET CLOSE on APRIL 17 RENO, Nev., April 10, 2024 (GLOBE NEWSWIRE) -- Monarch Casino & Resort, Inc. (NASDAQ: MCRI) announced today that it will release its 2024 first quarter financial results after the market closes on Wednesday, April 17, 2024. About Monarch Casino & Resort, Inc. Monarch Casino & Resort, Inc., through its subsidiaries, owns and operates the Monarch Casino Resort Spa Black Hawk ("Monarch Black Hawk") in Black Hawk, Colorado, approximately 40 miles west of Denver and the Atlantis Casino Resort Spa ("At...

 PRESS RELEASE

Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporti...

Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardless of underlying resistance mechanismValidation of novel translational assay enables detection and quantification of site-specific DNA methylation from liquid biopsies to assess target engagement of OTX-2002, our lead clinical-stage epigenomic controller CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (...

 PRESS RELEASE

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial...

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update Advanced OTX-2002 in MYCHELANGELO™ I trial; initial cohorts demonstrated encouraging disease control rate in late-stage HCC patientsEstablished a research collaboration with Novo Nordisk to develop an epigenomic controller for obesity, expanding the pipeline into the cardiometabolic space Announced strategic prioritization to focus resources on potential near-term value drivers, support long-term growth, and extend cash runway into Q1 2025 CAMBRIDGE, Mass., March 28, 2024 (GLOBE N...

 PRESS RELEASE

Omega Therapeutics Announces Two Poster Presentations at the American ...

Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024 CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego, California, April 5 – 10, 2024. The first poster will feature preclinical data validating a n...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch